Indication: 1. Used to treat viral or fungal infections that are difficult to control with certain antibiotics (such as herpes zoster, epidemic encephalitis B, Candida albicans infection, viral myocarditis, etc.). 2. Used as an adjuvant therapy for malignant tumors (mainly used for lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, etc.). 3. Used for immunodeficiency diseases (such as eczema, thrombocytopenia, multiple infection syndrome and chronic skin and mucosal fungal diseases), and also has a certain therapeutic effect on autoimmune diseases.

Indication: 1. Used to treat viral or fungal infections that are difficult to control with certain antibiotics (such as herpes zoster, epidemic encephalitis B, Candida albicans infection, viral myocarditis, etc.). 2. Used as an adjuvant therapy for malignant tumors (mainly used for lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, etc.). 3. Used for immunodeficiency diseases (such as eczema, thrombocytopenia, multiple infection syndrome and chronic skin and mucosal fungal diseases), and also has a certain therapeutic effect on autoimmune diseases.

Indication: 1. Used to treat viral or fungal infections that are difficult to control with certain antibiotics (such as herpes zoster, epidemic encephalitis B, Candida albicans infection, viral myocarditis, etc.). 2. Used as an adjuvant therapy for malignant tumors (mainly used for lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, etc.). 3. Used for immunodeficiency diseases (such as eczema, thrombocytopenia, multiple infection syndrome and chronic skin and mucosal fungal diseases), and also has a certain therapeutic effect on autoimmune diseases.

Indication: 1. Used to treat viral or fungal infections that are difficult to control with certain antibiotics (such as herpes zoster, epidemic encephalitis B, Candida albicans infection, viral myocarditis, etc.). 2. Used as an adjuvant therapy for malignant tumors (mainly used for lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, etc.). 3. Used for immunodeficiency diseases (such as eczema, thrombocytopenia, multiple infection syndrome and chronic skin and mucosal fungal diseases), and also has a certain therapeutic effect on autoimmune diseases.

Indication: It is clinically used to treat viral or fungal intracellular infections that are difficult to control with certain antibiotics (such as herpes zoster, epidemic encephalitis B, Candida albicans infection, viral myocarditis, etc.); it can be used as an adjuvant therapy for malignant tumors (mainly used for lung cancer, nasopharyngeal carcinoma, breast cancer, osteosarcoma, etc.); and it has a good therapeutic effect on immunodeficiency diseases (such as eczema, thrombocytopenia, multiple infection syndrome and chronic skin and mucosal fungal diseases).

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.

Indication: It is a first-line drug for the treatment of various solid tumors. Combination with VP-16 (EP regimen) is a first-line regimen for the treatment of SCLC or NSCLC. Combination with MMC, IFO (IMP regimen), or NVB is a common regimen for the treatment of NSCLC. Combination chemotherapy based on DDP is also the main treatment for advanced ovarian cancer, osteosarcoma and neuroblastoma. Combination with ADM, CTX, etc. is effective for squamous cell carcinoma and transitional cell carcinoma in multiple sites, such as head and neck, cervix, esophagus and urinary system tumors. "PVB" (DDP, VLB, BLM) can treat most stage IV non-spermatogonia testicular cancers with a remission rate of 50% to 80%. In addition, this product is a radiotherapy sensitizer. It is currently widely used in foreign countries for local radiotherapy of stage IV inoperable NSCLC, which can improve efficacy and survival.